KMDA
Kamada
NASDAQ: KMDA · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$8.14
+0.37% today
Updated 2026-04-30
Market cap
$474.09M
P/E ratio
23.43
P/S ratio
2.63x
EPS (TTM)
$0.35
Dividend yield
3.05%
52W range
$6 – $9
Volume
0.1M
WallStSmart proprietary scores
53
out of 100
Grade: C
Hold
Investment rating
5.3
Growth
C+8.5
Quality
A5.5
Profitability
C+7.3
Valuation
B+4/9
Piotroski F-Score
Moderate
2.5
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$13.00
+59.71%
12-Month target
$7.06
-13.27%
Intrinsic (DCF)
$11.83
Margin of safety
+29.33%
0 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Free cash flow $4.96M — positive
+ Revenue growth 14.50% QoQ
+ 29.33% below intrinsic value
+ Debt/equity 0.04x — low leverage
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $129.34M | $142.52M | $160.95M | $195.34M | $180.46M |
| Net income | $-2.32M | $8.28M | $14.46M | $21.86M | $3.64M |
| EPS | — | — | — | — | $0.35 |
| Free cash flow | $24.80M | $-1.53M | $36.85M | $16.93M | $4.96M |
| Profit margin | -1.79% | 5.81% | 8.99% | 11.19% | 11.20% |
Peer comparison
Smart narrative
Kamada trades at $8.14. representing a P/E of 23.43x trailing earnings. Our Smart Value Score of 53/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 2.49, it sits in the grey zone. TTM revenue stands at $180.46M. with profit margins at 11.20%. Our DCF model estimates intrinsic value at $11.83.
Frequently asked questions
What is Kamada's stock price?
Kamada (KMDA) trades at $8.14.
Is Kamada overvalued?
Smart Value Score 53/100 (Grade C, Hold). DCF value $11.83.
What is the price target of Kamada (KMDA)?
The analyst target price is $13.00, representing +59.7% upside from the current price of $8.14.
What is the intrinsic value of Kamada (KMDA)?
Based on our DCF model, intrinsic value is $11.83, a +29.3% margin of safety versus $8.14.
What is the future stock price of KMDA by 2030?
Our revenue-driven model estimates Kamada could reach $11.18 by 2030, based on historical CAGR, margin trends, and capped P/E multiples.
What is Kamada's revenue?
TTM revenue is $180.46M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
2.49 — grey zone.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2.63x
ROE7.64%
Beta0.31
50D MA$8.59
200D MA$7.59
Shares out0.06B
Float0.01B
Short ratio—
Avg volume0.1M
Performance
1 week+0.99%
1 month+0.61%
3 months-7.55%
YTD+16.15%
1 year—
3 years—
5 years—